source
- FDA approves Vera Therapeutics' Trutakna for IgA nephropathy, pricing set at $425,000 per yearThe U.S. Food and Drug Administration has granted approval to Trutakna, a new therapy from Vera Therapeutics, for the treatment of IgA nephropathy. IgA nephropathy is a kidney disorder where immun…
- Arbitration panel rules Prime Medicine did not breach Beam deal over AATD therapyAn arbitration panel has ruled that Prime Medicine did not violate its 2019 collaboration agreement with Beam Therapeutics by advancing a treatment for alpha‑1 antitrypsin deficiency (AATD). The de…